ICER Releases Final Report on Unsupported Price Increases in California
October 20, 2022
In the US, prescription drugs tend to increase in price faster than inflation and launch for prices far exceeding value to patients. In a newly released final report, ICER investigated unsupported price increases in California using data made available by SB-17, a law ensuring the transparency of drug costs from manufacturers and payers.
According to the report, “ICER’s review started with the top 25 specialty drugs and top 25 branded drugs from the SB-17 lists and removed any drug that was determined to have had a national price increase net of discounts less than 2% above the rate of medical inflation. ICER then created a list of 10 specialty and brand drugs with the most significant year-over-year spending increases. Manufacturer feedback on net price increases eliminated the majority of drugs from this list, leaving 3 drugs for review. Manufacturers of these drugs had the opportunity to provide evidence that could justify price increases.”
To read more, click here.
(Source: ICER, October 20th, 2022)